FDA adds rare vision-loss warning to popular GLP-1 weight loss drugs
WASHINGTON (AP) – Popular weight loss drugs, including Ozempic and Wegovy, will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, United States health regulators announced on Monday. The Food and Drug Administration said the risk will be added to the labeling of all GLP-1 drugs, the blockbuster medications used to treat obesity, diabetes and several other medical conditions. The class includes a dozen injectable or pill-based drugs, including widely used brands like Zepbound and Mounjaro.